论文部分内容阅读
采用改良的ＭＶ１ＬＵ细胞生长抑制ＭＴＴ法，检测了１０８例病毒性肝炎患者血清ＴＧＦ－β活性和血清ＰＣⅢ、ＨＡ、ＬＮ的含量，结果表明各型肝炎患者血清ＴＧＦ－β活性较正常对照都明显增高（Ｐ＜０．０１）。随病情的发展，ＴＧＦ－β１活性逐渐增高，ＰＣⅢ、ＨＡ、ＬＮ含量也明显增加，慢迁肝、慢活肝、肝硬化各组间ＴＧＦ－β１活性和ＰＣⅢ、ＨＡ、ＬＮ含量均有显著性差异（Ｐ＜０．０１），并呈正相关。肝硬化合并肝癌患者血清ＴＧＦ－β活性较正常对照增加１０倍以上。作者认为ＴＧＦ－β１活性可较好地反映肝纤维化进展状况，是调控肝纤维化的重要因子；肝硬化合并肝癌时，ＴＧＦ－β１活性显著增高，提示其可作为肝癌诊断、预后判断的另一指标。
Using modified MV1LU cell growth inhibition MTT assay, the serum levels of TGF-β and serum PCⅢ, HA and LN in 108 patients with viral hepatitis were measured. The results showed that serum TGF-β activity in patients with various hepatitis was significantly higher than that in normal control (P <0.01). With the progression of the disease, the activity of TGF-β1 gradually increased and the content of PCⅢ, HA and LN also increased obviously. The contents of TGF-β1, PCⅢ, HA and LN in slow-moving liver, slow-living liver and cirrhosis were significantly higher Difference (P <0.01), and was positively correlated. Serum TGF-β activity in cirrhotic patients with hepatocellular carcinoma was more than 10 times higher than that in normal controls. The authors believe that TGF-β1 activity can better reflect the progress of liver fibrosis, is an important factor in the regulation of liver fibrosis; cirrhosis combined with liver cancer, TGF-β1 activity was significantly increased, suggesting that it can be used as a diagnosis of liver cancer, the prognosis of the other An indicator.